BioXcel Therapeutics Inc (BTAI)
BioXcel Therapeutics, Inc. is a NASDAQ-listed common equity security representing a biopharmaceutical company focused on applying artificial intelligence methods to drug development in neuroscience and immuno-oncology. Through the company and its subsidiary, OnkosXcel Therapeutics LLC, the business develops and commercializes therapies for serious medical conditions in the United States. Its marketed product includes IGALMI, a sublingual film approved for the acute treatment of agitation linked to schizophrenia or bipolar I or II disorder in adults. The company also advances a pipeline of investigational programs, including BXCL501 for multiple neuropsychiatric and substance-use related indications, BXCL701 for certain cancers, and additional candidates BXCL502, BXCL503, and BXCL504 in dementia-related and stress-related disorders. BioXcel Therapeutics was incorporated in 2017 and is headquartered in New Haven, Connecticut.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-BTAI
|
$0.079
|
6.4% Upside
|
Fair
|
$5 6,656.8% Upside
|
Not available
|
Bargain
|
Weak
|
0.0%
|
November 18, 2026
|
3.1x
|
2.313 M
|
93.927 M
|
97.8%
|
85.9%
|
-45.9
|
71.8%
|
